Balyasny Asset Management
DAWN

Balyasny Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Balyasny Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.3M Buy
2,625,235
+1,135,311
+76% +$16M 0.07% 311
2025
Q4 		$13.9M Buy
1,489,924
+105,877
+8% +$885K 0.02% 884
2025
Q3 		$9.76M Buy
+1,384,047
New +$9.52M 0.01% 1068
2025
Q2 		– Sell
-133,641
Closed -$1.06M – 2926
2025
Q1 		$1.06M Buy
133,641
+104,186
+354% +$1.12M ﹤0.01% 1963
2024
Q4 		$373K Buy
+29,455
New +$410K ﹤0.01% 2300
2024
Q2 		– Sell
-53,152
Closed -$878K – 2663
2024
Q1 		$878K Buy
53,152
+37,547
+241% +$562K ﹤0.01% 1847
2023
Q4 		$228K Buy
+15,605
New +$189K ﹤0.01% 2272
2023
Q1 		– Sell
-9,883
Closed -$213K – 2747
2022
Q4 		$213K Buy
+9,883
New +$203K ﹤0.01% 2116

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management's DAWN Position: Q1 2026 in Review

Balyasny Asset Management increased its Day One Biopharmaceuticals (DAWN) stake by 76% in Q1 2026, buying an estimated $16M and bringing the position to 2,625,235 shares worth $56.3M. The position accounts for 0.07% of the portfolio, ranked #311.

Balyasny Asset Management first reported a position in DAWN in Q4 2022 and has held it in 8 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Balyasny Asset Management held 2,625,235 shares of Day One Biopharmaceuticals worth $56.3M as of Q1 2026.
  • Balyasny Asset Management bought 1,135,311 Day One Biopharmaceuticals shares in Q1 2026, an estimated $16M.
  • Day One Biopharmaceuticals made up 0.07% of Balyasny Asset Management's portfolio in Q1 2026, its #311 holding.
  • Balyasny Asset Management first reported a position in Day One Biopharmaceuticals in Q4 2022 and has held it in 8 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.